Kuan Wei-Li, Zhao Jing-Wei, Barker Roger A
Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK.
Psychopharmacology (Berl). 2008 Apr;197(2):279-93. doi: 10.1007/s00213-007-1030-6. Epub 2007 Dec 23.
Levodopa-induced dyskinesia (LID) is an inevitable complication of the long-term treatment of Parkinson's disease (PD) with levodopa. In a rat model of LID, we observed that animals of almost identical genetic but slightly different environmental backgrounds displayed a very different profile in terms of their development and severity of LID.
We hypothesised that this heterogeneity can be attributed to different levels of anxiety in individual animals. We evaluated the basal anxiety level of rats in this study using the elevated plus maze (EPM), open field (OF) test, and plasma corticosterone level. These animals then received unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway after which they were primed to develop LID. Finally, we manipulated the anxiety level of these animals by citalopram treatment over a 9-week period before they were killed.
Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals. Furthermore, this citalopram-mediated LID recovery appeared to be independent of any changes in striatal cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) and cyclin-dependent kinase 5 (Cdk5) system, in contrast to our previous studies with fetal ventral mesencephalon transplants. However, chronic citalopram treatment almost completely abolished the expression of serotonin receptor 1B (5HT1B) in the striatum in animals exhibiting LID recovery.
These results indicate a novel association of serotonin receptors in the development of LID and contributes to the evidence that the serotonergic system may play an important role in such movements.
左旋多巴诱导的异动症(LID)是帕金森病(PD)长期使用左旋多巴治疗不可避免的并发症。在LID大鼠模型中,我们观察到基因几乎相同但环境背景略有不同的动物在LID的发展和严重程度方面表现出非常不同的特征。
我们假设这种异质性可归因于个体动物不同程度的焦虑。在本研究中,我们使用高架十字迷宫(EPM)、旷场试验(OF)和血浆皮质酮水平评估大鼠的基础焦虑水平。这些动物随后接受黑质纹状体通路的单侧6-羟基多巴胺损伤,之后引发LID。最后,在处死这些动物前的9周时间里,我们通过西酞普兰治疗来控制它们的焦虑水平。
虽然我们未能在大鼠的焦虑水平与LID的发作或严重程度之间建立关联,但我们的结果表明,慢性治疗后西酞普兰能够部分缓解LID,且恢复程度与个体动物的焦虑指标呈负相关。此外,与我们之前关于胎儿腹侧中脑移植的研究不同,这种西酞普兰介导的LID恢复似乎与纹状体中32 kDa的环磷酸腺苷调节磷蛋白(DARPP-32)和细胞周期蛋白依赖性激酶5(Cdk5)系统的任何变化无关。然而,慢性西酞普兰治疗几乎完全消除了表现出LID恢复的动物纹状体中5-羟色胺受体1B(5HT1B)的表达。
这些结果表明5-羟色胺受体在LID发展过程中存在新的关联,并为5-羟色胺能系统可能在此类运动中起重要作用提供了证据。